Real-world efficacy and safety of peptide receptor radionuclide therapy (PRRT) with 177Lu-Dotatate (Lutathera) (LU) in neuroendocrine tumors (NETs)

被引：0
|
作者：
Navarro Martin, M. [1 ]
Teran Brage, E. [1 ]
Campana-Diaz, E. [2 ]
Garcia-Talavera, P. [2 ]
Reguera Puertas, P. [1 ]
Rama-Alonso, S. [2 ]
Garijo-Martinez, M. C. [1 ]
Felix, L. C. [1 ]
Diaz Sanchez, P. [1 ]
Vidal Tocino, R. [1 ]
Fonseca Sanchez, E. [1 ]
机构：
[1] Univ Hosp Salamanca, Dept Med Oncol, Salamanca, Spain
[2] Univ Hosp Salamanca, Dept Nucl Med, Salamanca, Spain
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.227
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
219P
引用
收藏
页码：S95 / S95
页数：1
相关论文
共 50 条
  • [21] Peptide receptor radionuclide therapy (PRRT) using 177Lu-Dotatate:: Early clinical and dosimetric results
    Garkavij, M.
    Sjogreen-Gleisner, K.
    Nickel, M.
    Ohlsson, T.
    Wingardh, K.
    Tennvall, J.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2008, 23 (04) : 524 - 525
  • [22] Safety of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease
    Alsadik, Shahad
    Gnanasegaran, Gopinath
    Chen, Luohai
    Mandair, Dalvinder
    Toumpanakis, Christos
    Caplin, Martyn
    Navalkissoor, Shaunak
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (10) : 1503 - 1508
  • [23] A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients
    Becx, Morticia N.
    Minczeles, Noemie S.
    Brabander, Tessa
    de Herder, Wouter W.
    Nonnekens, Julie
    Hofland, Johannes
    CANCERS, 2022, 14 (23)
  • [24] The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis
    Jie Zhang
    Qi Song
    Liang Cai
    Ying Xie
    Yue Chen
    Journal of Cancer Research and Clinical Oncology, 2020, 146 : 1533 - 1543
  • [25] The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis
    Zhang, Jie
    Song, Qi
    Cai, Liang
    Xie, Ying
    Chen, Yue
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (06) : 1533 - 1543
  • [26] Real-world efficacy and safety of peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Abou Jokh Casas, Estephany
    Martinez, Nieves Purificacion
    Herranz, Urbano Anido
    Cabezas Agricola, Jose Manuel
    Ferreiro, Silvia Varela
    Maseda, Alberto Carral
    Calvo, Ovidio Fernandez
    Mato Mato, Jose Antonio
    Seoane, Zulema Nogareda
    Martinez de LLano, Sofia Rodriguez
    Varela, Maria Quindos
    Baron, Francisco
    Fonseca, Omar Rodriguez
    Castineira, Antia Cousillas
    Garcia, Gloria Muniz
    De Matias Leralta, Jose Maria
    Catalina, Pablo Fernandez
    Cameselle Teijeiro, Jose Manuel
    Bernardez, Beatriz
    Nunez, Virginia Pubul
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [27] PFS and OS after Salvage Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors (GEP-NETs) - The Rotterdam Cohort
    Van der Zwan, W.
    Brabander, T.
    Kam, B.
    Teunissen, J.
    Krenning, E.
    Kwekkeboom, D.
    de Herder, W.
    NEUROENDOCRINOLOGY, 2018, 106 : 262 - 262
  • [28] Validation of a Clinical Score (CS) for Patients With Well-Differentiated Neuroendocrine Tumors (WD NETs) Under Consideration for Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Dotatate
    Das, Satya
    Chauhan, Aman
    Du, Liping
    Thomas, Katharine E.
    Jacob, Aasems
    Schad, Aimee
    Jain, Shikha
    Jessop, Aaron
    Shah, Chirayu
    Eisner, David
    Cardin, Dana B.
    Ciombor, Kristen K.
    Goff, Laura W.
    Bradshaw, Marques
    Delbeke, Dominique
    Sandler, Martin
    Berlin, Jordan
    Ramirez, Robert A.
    PANCREAS, 2022, 51 (03) : E41 - E41
  • [29] Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting
    Kalshetty, Ashwini
    Ramaswamy, Anant
    Ostwal, Vikas
    Basu, Sandip
    NUCLEAR MEDICINE COMMUNICATIONS, 2018, 39 (12) : 1143 - 1149
  • [30] Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
    Parghane, Rahul V.
    Talole, Sanjay
    Prabhash, Kumar
    Basu, Sandip
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (06) : 428 - 435
12345